Chronic myeloid leukemia in the imatinib era.
作者信息
Druker Brian J
机构信息
Howard Hughes Medical Institute and the School of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA.
出版信息
Semin Hematol. 2003 Apr;40(2 Suppl 2):1-3. doi: 10.1053/shem.2003.50033.
PMID:12783367
Abstract
The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.
摘要
Zotero 插件